Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 7/20 | 0.50 |
| ▸ | CA2 | P00918 | 7/20 | 0.50 |
| ▸ | CA4 | P22748 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17879692 | 0.87 | CA1 (0.60) | CA1CA2CA4ALDH1A1MAPK1 | |
| SCHEMBL8016080 | 0.85 | ALDH1A1 (0.54) | CA1CA2CA4ALDH1A1MAPK1 | |
| SCHEMBL339168 | 0.85 | ALDH1A1 (0.61) | CA1CA2CA4ALDH1A1MAPK1 | |
| SCHEMBL28893742 | 0.82 | HTT (0.52) | CA1CA2CA4ALDH1A1MAPK1 | |
| SCHEMBL13130804 | 0.82 | ALDH1A1 (0.45) | CA1CA2CA4ALDH1A1MAPK1 | |
| SCHEMBL19631329 | 0.81 | HDAC3 (0.47) | CA1CA2CA4ALDH1A1MAPK1 | |
| SCHEMBL24996860 | 0.80 | ALDH1A1 (0.56) | ALDH1A1MAPK1L3MBTL1ITGB3ITGA2B | |
| SCHEMBL3364814 | 0.80 | ALDH1A1 (0.56) | ALDH1A1MAPK1L3MBTL1ITGB3ITGA2B | |
| SCHEMBL3093075 | 0.80 | CA1 (0.68) | CA1CA2CA4ALDH1A1MAPK1 | |
| SCHEMBL24810919 | 0.80 | ALDH1A1 (0.56) | ALDH1A1MAPK1L3MBTL1ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140193510-A1 | Polymer-Agent Conjugates, Particles, Compositions, and Related Methods of Use | CERULEAN PHARMA INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140193510-A1 | Polymer-Agent Conjugates, Particles, Compositions, and Related Methods of Use | CERULEAN PHARMA INC. (US) | 2014-07-10 | — | — | US | disclosed |
| WO-2010114770-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. (US) | 2010-10-07 | — | — | WO | disclosed |
| US-20100247669-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. | 2010-09-30 | — | — | US | disclosed |
| US-20100247669-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100247669-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | LPXN, POLI, BRCA1 | CA1 2165/4885CA2 4355/4885CA4 1677/4885 |
| US-20140193510-A1 | Polymer-Agent Conjugates, Particles, Compositions, and Related Methods of Use | LPXN, POLI, BRCA1 | CA1 2165/4885CA2 4355/4885CA4 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.